Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Rare Diseases FDA Regulation

Center Of Excellence Not Best Model For US FDA Rare Disease Program, Woodcock Says

  • Analysis

Executive Summary

Center for Drug Evaluation and Research Director says rare disease reviews need multiple specialists, which likely would not fit into a centralized rare disease review group.
Table

View full table

Advertisement

Related Content

Pink Sheet
US FDA May Create Rare Disease Expert Pool For Advisory Committee Reviews
Pink Sheet
US FDA Appoints Another Orphan Products Development Office Head Amid Growth Expectations
Pink Sheet
US FDA's Streamlined Hiring Pilot Restarts After Delay
Pink Sheet
US FDA Reorg: Centers Will Report Directly To Gottlieb; 'Flattened' Structure Will Make Future Political Transitions Easier
Pink Sheet
US FDA's Rare Diseases Program Not Expected To Change With Drug Office Reorg
Pink Sheet
US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say
Pink Sheet
US FDA May Create Immunology, Neuroscience Centers Of Excellence
Pink Sheet
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Pink Sheet
FDA Says Goodbye To Its Antiviral Drugs Advisory Committee
Pink Sheet
FDA DRUG ADVISORY COMMITTEES SHOULD NOT BE DISMANTLED, NDMA URGES

Topics

Advertisement
Tags:
Rare Diseases FDA Regulation
UsernamePublicRestriction

Register

PS123867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By